Post-transplant lymphoproliferative disorder after pediatric liver transplantation: Characteristics and outcome

Pediatric Transplantation

Volumn 13, Issue 3, 2009, Pages 307-310

  Fernández, María C ^a   Bes, David ^a   De Dávila, María ^a   López, Susana ^a   Cambaceres, Carlos ^a   Dip, Marcelo ^a   Imventarza, Oscar ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Epstein Barr virus infections; Outcome; Pediatric liver transplantation; Post transplant lymphoproliferative

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; GANCICLOVIR; METHYLPREDNISOLONE; OKT 3; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS; VINCRISTINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; IMMUNOHISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER GRAFT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; PHYSICAL EXAMINATION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; RISK FACTOR; TUMOR LYSIS SYNDROME; VIRUS INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; LIVER DISEASES; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 64149090336     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.00914.x     Document Type: Article

References (14)

1. Malatack JJ, Gaerner JC, Urbach AH, et al. Orthotopic liver transplantation Epstein-Barr virus, cyclosporine and lymphoproliferative disease: A growing concern. J Pediatr 1991 : 118 : 667 675.
2. Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002 : 6 : 456 464.
3. Ho M, Jaffe R, Miller Gelal. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988 : 45 : 719 727.
4. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver recipients receiving primary Tacrolimus (FK 506) therapy. Transplantation 1998 : 66 : 1047 1052.
5. Cox HL, Lawrence-Miyasaki LS, Garcia-Kennedy R, et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK 506 after liver transplantation. Transplantation 1995 : 59 : 524 529.
6. Fellner MD, Durand K, Correa M, et al. A semi-quantitative PCR method (SQ-PCR) to measure Epstein-Barr (EBV) load: Its application in transplant patients. J Clin Virol 2003 : 28 : 323 330.
7. Randhawa PS, Jaffe ES, Deametris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplant lymphoproliferative disease. N Engl J Med 1992 : 327 : 1710 1714.
8. Jaffe ES, Harris NL, Stein H, Vardim JW (eds World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon : IARC Press 2001.
9. Collins MH, Montone KT, Leahey AM, et al. Post-transplant lymphoproliferative disease in children. Pediatr Transplant 2001 : 5 : 250 257.
10. Green M, Michaels MG, Webber SA, et al. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 1999 : 3 : 271 281.
11. Green M. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation. Am J Transplant 2001 : 1 : 103 108.
12. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996 : 62 : 370 375.
13. Hurwitz M, Desai DM, Cox KL, et al. Complete immunosuppressive withdrawal as uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004 : 8 : 210 213.
14. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK 506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant 2001 : 5 : 359 364.